Overview

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer

Status:
Not yet recruiting

Trial end date:
2025-02-20

Target enrollment:

Participant gender:

Summary

This is a prospective, single-institution, single-arm, phase II clinical trial that tests a novel strategy of neoadjuvant Sasanlimab, an immune checkpoint inhibitor (ICI), in combination with stereotactic body radiation therapy as an in-situ vaccination in patients, who are ineligible to receive cisplatin-based chemotherapy and undergoing radical cystectomy for muscle-invasive bladder cancer.

Phase:

Phase 2

Details

Lead Sponsor:

The Methodist Hospital Research Institute

Collaborator:

Pfizer

Treatments:

Immune Checkpoint Inhibitors